Attempts 4CMenB vaccine, the first vaccine against meningitis B has shown promising results that could help fight disease and save the lives of hundreds of children each year. The results presented at the European Society for Infectious Diseases in Children in The Hague, has shown that the vaccine was effective in preventing about 80 percent in 1000 strains of meningitis B in different parts of Europe.
The results are exciting and it's a very positive step in the fight to eradicate meningitis B, which is the biggest killer of all types of meningitis in Britain, said Steve Dayman, meningitis in the UK charity. This vaccine is the first of its kind and has the potential to save thousands of lives. Meningitis B is very deadly and can kill babies and toddlers aged less than four hours. More than 10 percent of victims are killed by the disease, with about 15 percent of survivors are disabled and suffer from long-term effects.
There are several types of meningitis caused by different microorganisms. B meningococcus is the most common form of bacterial meningitis, and the most difficult challenge for scientists because there are so many strains to target.
Although vaccination programs have been successfully introduced to the fight against pneumococcal meningitis C and Hib strains and B there is no vaccine currently exists. The results of 1800 children found that the vaccine worked well, alone or in conjunction with vaccines for other strains of the disease.
Another 1500 study found that babies that provide protection when administered as a booster, while others showed an immune response in adolescents. 4CMenB was developed by Novartis, has applied for a marketing license for the European Medicines Agency to cover the United Kingdom. The vaccine was developed using a reverse vaccinology is called, to decode the genome sequence of meningococcal B and selecting proteins most likely to be broadly effective vaccine candidates.
It could give the children from the age of two months in three booster doses a year. Sometimes invaded and inflames the membranes surrounding the brain and spinal cord. In mild cases respond quickly to antibiotic treatment, but the most serious of developing meningococcal blood poisoning when the blood is contaminated. Sue Weston, Director General of charity, Meningitis Trust, said: A vaccine would greatly reduce the level of suffering that we see every day.
Related Stories:
The results are exciting and it's a very positive step in the fight to eradicate meningitis B, which is the biggest killer of all types of meningitis in Britain, said Steve Dayman, meningitis in the UK charity. This vaccine is the first of its kind and has the potential to save thousands of lives. Meningitis B is very deadly and can kill babies and toddlers aged less than four hours. More than 10 percent of victims are killed by the disease, with about 15 percent of survivors are disabled and suffer from long-term effects.
There are several types of meningitis caused by different microorganisms. B meningococcus is the most common form of bacterial meningitis, and the most difficult challenge for scientists because there are so many strains to target.
Although vaccination programs have been successfully introduced to the fight against pneumococcal meningitis C and Hib strains and B there is no vaccine currently exists. The results of 1800 children found that the vaccine worked well, alone or in conjunction with vaccines for other strains of the disease.
Another 1500 study found that babies that provide protection when administered as a booster, while others showed an immune response in adolescents. 4CMenB was developed by Novartis, has applied for a marketing license for the European Medicines Agency to cover the United Kingdom. The vaccine was developed using a reverse vaccinology is called, to decode the genome sequence of meningococcal B and selecting proteins most likely to be broadly effective vaccine candidates.
It could give the children from the age of two months in three booster doses a year. Sometimes invaded and inflames the membranes surrounding the brain and spinal cord. In mild cases respond quickly to antibiotic treatment, but the most serious of developing meningococcal blood poisoning when the blood is contaminated. Sue Weston, Director General of charity, Meningitis Trust, said: A vaccine would greatly reduce the level of suffering that we see every day.
Related Stories:
